LON:AREC Arecor Therapeutics (AREC) Share Price, News & Analysis GBX 62.10 +3.10 (+5.25%) As of 11:34 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Arecor Therapeutics Stock (LON:AREC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arecor Therapeutics alerts:Sign Up Key Stats Today's Range 58▼ 64.4950-Day Range 42▼ 62.1052-Week Range 35.40▼ 95Volume184,495 shsAverage Volume26,347 shsMarket Capitalization£23.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com Read More Receive AREC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arecor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AREC Stock News HeadlinesArecor Therapeutics And 2 Other UK Penny Stocks To ConsiderJuly 31, 2025 | finance.yahoo.comSkye and Arecor to develop higher formulation of CB1 inhibitorMay 20, 2025 | finance.yahoo.comFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft. But one controversial analyst, known for predicting the collapses of Fannie Mae, GM, and others, is issuing a serious warning. He believes Nvidia’s rise has masked a dangerous flaw—and that the stock could fall 50% or more from current levels.August 8 at 2:00 AM | Porter & Company (Ad)Arecor Chair Increases Stake with Share PurchaseMay 14, 2025 | tipranks.comSMALL-CAP MOVERS: Is popping AIM ready to really blow up? One research house reckons soMay 10, 2025 | uk.investing.comSMALL CAP MOVERS: Is 'oversold' AIM market due a comeback story?May 9, 2025 | msn.comArecor Therapeutics Full Year 2024 Earnings: Misses ExpectationsApril 23, 2025 | finance.yahoo.comArecor Therapeutics strikes deal for development of peptide therapyMarch 12, 2025 | lse.co.ukSee More Headlines AREC Stock Analysis - Frequently Asked Questions How have AREC shares performed this year? Arecor Therapeutics' stock was trading at GBX 73.75 at the beginning of 2025. Since then, AREC shares have decreased by 15.8% and is now trading at GBX 62.10. How were Arecor Therapeutics' earnings last quarter? Arecor Therapeutics plc (LON:AREC) released its quarterly earnings data on Tuesday, April, 22nd. The company reported ($0.31) EPS for the quarter. Arecor Therapeutics had a negative trailing twelve-month return on equity of 118.67% and a negative net margin of 176.89%. How do I buy shares of Arecor Therapeutics? Shares of AREC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Arecor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arecor Therapeutics investors own include Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Advanced Micro Devices (AMD), Cisco Systems (CSCO), Lowe's Companies (LOW) and SNDL (SNDL). Company Calendar Last Earnings4/22/2025Today8/08/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryCoal Current SymbolLON:AREC CIKN/A Webwww.americanresourcescorp.com Phone44 1223 426 060FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (28.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£10.68 million Net Margins-176.89% Pretax MarginN/A Return on Equity-118.67% Return on Assets-37.31% Debt Debt-to-Equity Ratio5.51 Current Ratio1.37 Quick Ratio6.24 Sales & Book Value Annual Sales£6.04 million Price / Sales3.88 Cash FlowGBX 12.25 per share Price / Cash Flow5.07 Book ValueGBX 16.58 per share Price / Book3.75Miscellaneous Outstanding Shares37,756,599Free FloatN/AMarket Cap£23.45 million OptionableNot Optionable Beta-0.18 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (LON:AREC) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredChina's 500 Million Year AdvantageThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arecor Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Arecor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.